Related Experiment Video

Updated: May 30, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies

Timothy A Yap1, David Olmos, Lulama Rhoda Molife

  • 1Drug Development Unit, Royal Marsden NHS Foundation Trust, Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5PT, UK.

Expert Opinion on Investigational Drugs
|July 23, 2011
PubMed
Abstract

Insights

Targeting the insulin-like growth factor (IGF) pathway, particularly the IGF-I receptor (IGF-IR), shows promise in cancer treatment. Continued research into combination therapies and predictive biomarkers is crucial for patient selection and improved outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Preclinical data strongly implicate the insulin-like growth factor (IGF) signaling pathway in cancer development and progression.
  • This has driven the development of targeted therapies against the IGF-I receptor (IGF-IR) over the last decade.

Purpose of the Study:

  • To review the structure and function of the IGF system and related pathways.
  • To discuss the rationale for targeting IGF-IR in cancer and current drug development advancements.
  • To examine the preclinical and clinical trial data for figitumumab, a leading IGF-IR targeting antibody.

Main Methods:

  • Literature review of the IGF system and its role in oncogenesis.
  • Analysis of preclinical data for IGF-IR targeted agents.
  • Evaluation of clinical trial outcomes for figitumumab (Phase I-III).

Main Results:

  • The IGF system and IGF-IR are implicated in cancer.
  • Figitumumab, an anti-IGF-IR monoclonal antibody, has undergone extensive preclinical and clinical evaluation.
  • Clinical development has shown both successes and failures.

Conclusions:

  • Targeted therapies for the IGF pathway warrant continued investigation.
  • Future strategies should emphasize combinatorial approaches.
  • Development of predictive biomarkers is essential for patient selection and enhancing antitumor responses.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...